Orion Corporation

Novartis Ag

Mitobridge, Inc.

Aurigene Oncology Limited

Sanjita Sasmal

Susanta Samajdar

Chandrasekhar Abbineni

Bharat Lagu

Subramanya Hosahalli

Mark G Bock

Arthur F Kluge

Muralidhara Ramachandra

Xinyuan Edward Wu

Thomas Ullrich

Chetan Pandit

Subhendu Mukherjee

Eric Bell

Leena Khare Satyam

Margaret Biddle

Takashi Ogiyama

Mark Gary Bock

The present invention provides pyridazine derivatives of formula (I), which are therapeutically useful as SMARCA2/4 degraders. These compounds are useful in the treatment and/or prevention of diseases or disorders dependent upon SMARCA2/4 in a mammal. The present invention also provides preparation of the compounds and pharmaceutical compositions comprising at least one of the pyridazine derivatives of formula (I) or a pharmaceutically acceptable salt, or a stereoisomer thereof.

Pyridazine derivatives as SMARCA2/4 degraders

The present invention provides a method of treating a disease or disorder with at least one SMARCA2/4 degrader, in a subject who are responders to such treatment based on the presence of tumor specific alterations described therein. The present invention also provides the methods for treating prostate cancer in the subjects who are likely to respond to treatment with SMARCA2/4 degraders.

Method for treating diseases using SMARCA2/4 degraders

The present invention is related to compounds of structure (I) as heme oxygenase 1 (HMOX 1) inducers. The present invention is also related a method of controlling the activity or the amount, or both the activity and the amount, of heme-oxygenase 1 in a mammalian subject. The definitions of the variables are provided herein.

HMOX1 inducers

The present disclosure provides bicyclic heterocyclic derivatives of formula (I), which may be therapeutically useful, more particularly as bromodomain inhibitors; (I), in which R, R, R, R, L, L, Cy, Cy, X, n, and dotted line have the same meaning given in the specification, and pharmaceutically acceptable salts or pharmaceutically acceptable stereoisomers thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in diseases or disorders associated as bromodomain inhibitors. The present disclosure also provides preparation of compounds and pharmaceutical formulations comprising at least one of bicyclic heterocyclic derivatives of formula (I), together with a pharmaceutically acceptable carrier, diluent, or excipient. 

Bicyclic heterocyclic derivatives as bromodomain inhibitors

The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I), in which the substituents are as defined in the specification; to compounds of formula (I) for use as androgen receptor modulators. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. 

Pyrazoline derivatives and their use as selective androgen receptor modulators

Growing community of inventors

Hyderabad Telangana, India

Sanjita Sasmal